methylcob(III)alaminWhat was measured
Measured, with no finding
1,487 endpoints
Show what was measuredHide what was measured
color vision
increases, p = 0.05
The methylprednisolone pulse treatment group showed faster recovery of visual function, particularly the visual acuity at 1 week (P<.05), Humphrey field analyzer mean deviation at 3 weeks (P<.05), and color vision at 1 week (P<.05)
PMID 10340796 · one of two readings recorded this
contrast sensitivity recovery
increases, p = 0.01
Recovery of contrast sensitivity at several different spatial frequencies was significant in the pulse treatment group at 1 (P<.01), 2 (P<.05), and 4 weeks (P<.05) after the start of treatment
PMID 10340796 · one of two readings recorded this
contrast sensitivity recovery
increases, p = 0.05
Recovery of contrast sensitivity at several different spatial frequencies was significant in the pulse treatment group at 1 (P<.01), 2 (P<.05), and 4 weeks (P<.05) after the start of treatment
PMID 10340796 · one of two readings recorded this
contrast sensitivity recovery
increases, p = 0.05
Recovery of contrast sensitivity at several different spatial frequencies was significant in the pulse treatment group at 1 (P<.01), 2 (P<.05), and 4 weeks (P<.05) after the start of treatment
PMID 10340796 · one of two readings recorded this
Humphrey field analyzer mean deviation
increases, p = 0.05
The methylprednisolone pulse treatment group showed faster recovery of visual function, particularly the visual acuity at 1 week (P<.05), Humphrey field analyzer mean deviation at 3 weeks (P<.05), and color vision at 1 week (P<.05)
PMID 10340796 · one of two readings recorded this
side effects frequency
increases, p = 0.05
Side effects appeared more frequently in the pulse treatment group than in the control (P<.05)
PMID 10340796 · one of two readings recorded this
visual acuity
increases, p = 0.05
The methylprednisolone pulse treatment group showed faster recovery of visual function, particularly the visual acuity at 1 week (P<.05), Humphrey field analyzer mean deviation at 3 weeks (P<.05), and color vision at 1 week (P<.05)
PMID 10340796 · one of two readings recorded this
visual function test results
no effect
Visual function test results at 12 weeks and 1 year were essentially the same in the two treatment groups
PMID 10340796 · one of two readings recorded this
visual function test results
no effect
Visual function test results at 12 weeks and 1 year were essentially the same in the two treatment groups
PMID 10340796 · one of two readings recorded this
neuropathic pain grading; ulnar motor and median sensory nerve conduction velocities in haemodialysis patients
increases, ulnar motor and median sensory nerve conduction velocities showed significant improvement after 6 months; single-arm, no control, n = 9
Not recorded as a finding: this platform holds no node for the endpoint
After 6 months of treatment, the patients' pain or paresthesia had lessened, and the ulnar motor and median sensory nerve conduction velocities showed significant improvement.
PMID 10411351 · one of two readings recorded this
pain or paresthesia
decreases
After 6 months of treatment, the patients' pain or paresthesia had lessened
PMID 10411351 · one of two readings recorded this
serum vitamin B12 concentration
increases
Serum concentrations of vitamin B12 were ultra-high during treatment due to the lack of urinary excretion
PMID 10411351 · one of two readings recorded this
ulnar motor and median sensory nerve conduction velocities
increases
the ulnar motor and median sensory nerve conduction velocities showed significant improvement
PMID 10411351 · one of two readings recorded this
neurogenic claudication distance
increases, n = 152
there was no significant difference between the 2 groups in terms of pain improvement and neurological signs, except neurogenic claudication distance which was better in the M-group
PMID 10998833 · one of two readings recorded this
neurological signs
no effect, n = 152
there was no significant difference between the 2 groups in terms of pain improvement and neurological signs, except neurogenic claudication distance which was better in the M-group
PMID 10998833 · one of two readings recorded this
pain improvement, neurological signs and neurogenic claudication distance in degenerative lumbar spinal stenosis (instrument not stated)
no effect
Not recorded as a finding: this platform holds no node for the endpoint
Most of the patients in both groups showed improvement but there was no significant difference between the 2 groups in terms of pain improvement and neurological signs, except neurogenic claudication distance which was better in the M-group.
PMID 10998833 · one of two readings recorded this
pain improvement
no effect, n = 152
there was no significant difference between the 2 groups in terms of pain improvement and neurological signs, except neurogenic claudication distance which was better in the M-group
PMID 10998833 · one of two readings recorded this
coldness response rate
increases
Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)
PMID 11798619 · one of two readings recorded this
dysuria response rate
increases
Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)
PMID 11798619 · one of two readings recorded this
hotness response rate
increases
Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)
PMID 11798619 · one of two readings recorded this
hypoesthesia response rate
increases
Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)
PMID 11798619 · one of two readings recorded this
improvement of spontaneous pain and numbness of limbs and other neuropathic symptoms, nerve reflection and conduction velocity, mecobalamin versus vitamin B12 (active control)
increases
Not recorded as a finding: this platform holds no node for the endpoint
Twelve weeks after the treatment, spontaneous pain and numbness of limbs were improved by 73% and 75% in the mecobalamin group, which were much higher than those in the controls (36% and 45% respectively).
PMID 11798619 · one of two readings recorded this
nerve reflection and conduction velocity
increases
Mecobalamin also benefited nerve reflection and conduction velocity to a certain extent
PMID 11798619 · one of two readings recorded this
numbness of limbs improvement rate
increases
spontaneous pain and numbness of limbs were improved by 73% and 75% in the mecobalamin group, which were much higher than those in the controls (36% and 45% respectively)
PMID 11798619 · one of two readings recorded this
oral dryness response rate
increases
Hypoesthesia, hotness, coldness, oral dryness and dysuria showed better response in the mecobalamin group than in the controls (55% vs 25%, 52% vs 18%, 59% vs 30%, 53% vs 19%, 63% vs 20% respectively)
PMID 11798619 · one of two readings recorded this
spontaneous pain improvement rate
increases
spontaneous pain and numbness of limbs were improved by 73% and 75% in the mecobalamin group, which were much higher than those in the controls (36% and 45% respectively)
PMID 11798619 · one of two readings recorded this
fasting total homocysteine before vs after therapy
decreases, p = 0.003
Mean tHcy levels showed a significant decrease in group A from 22.5 +/- 15.6 to 10.2 +/- 3.1 micromol/l (p = 0.003)
PMID 12021520 · one of two readings recorded this
fasting total homocysteine before vs after therapy
decreases, p = 0.012
and in group B from 19.9 +/- 4.0 to 11.2 +/- 1.9 micromol/l (p = 0.012)
PMID 12021520 · one of two readings recorded this
fasting total homocysteine before vs after therapy
no effect
no significant changes were observed in groups C (25.9 +/- 9.3 vs. 27.3 +/- 9.7 micromol/l, p = n.s.)
PMID 12021520 · one of two readings recorded this
fasting total homocysteine before vs after therapy
no effect
and D (26.6 +/- 14.3 vs. 24.3 +/- 11.8 micromol/l, p = n.s.)
PMID 12021520 · one of two readings recorded this
final fasting total homocysteine
no effect
similar to group B (11.2 +/- 1.9 micromol/l, p = n.s.)
PMID 12021520 · one of two readings recorded this
final fasting total homocysteine
decreases, p = 0.001
Final tHcy levels were significantly lower in group A (10.2 +/- 3.1 micromol/l) compared to groups C (27.3 +/- 9.7 micromol/l, p < 0.001)
PMID 12021520 · one of two readings recorded this
final fasting total homocysteine
decreases, p = 0.001
group A (10.2 +/- 3.1 micromol/l) compared to groups C (27.3 +/- 9.7 micromol/l, p < 0.001) and group D (24.3 +/- 11.8 micromol/l, p < 0.001)
PMID 12021520 · one of two readings recorded this
motor and sensory nerve conduction
no effect
Motor and sensory nerve conduction studies showed no statistical improvement after 4 months
PMID 1324807 · one of two readings recorded this
somatic and autonomic symptoms and signs of diabetic neuropathy
decreases
In a double-blind study, the active group showed statistical improvement in the somatic and autonomic symptoms with regression of signs of diabetic neuropathy
PMID 1324807 · one of two readings recorded this
somatic and autonomic symptoms of diabetic neuropathy; motor and sensory nerve conduction studies
no effect, nerve conduction showed no statistical improvement after 4 months
Not recorded as a finding: this platform holds no node for the endpoint
Motor and sensory nerve conduction studies showed no statistical improvement after 4 months.
PMID 1324807 · one of two readings recorded this
serum tHcy, sublingual versus oral
no effect
There was no statistically significant difference in serum tHcy concentrations between SL and PO groups either before or after treatment
PMID 17109579 · one of two readings recorded this
total serum homocysteine (tHcy)
decreases
A statistically significant reduction in tHcy values was observed in both groups upon completion of the 6-week protocol
PMID 17109579 · one of two readings recorded this
plasma folic acid and methylcobalamin levels
decreases, p = 0.05
After 12-week treatment the plasma folic acid and methylcobalamin, and Hcy levels decreased and serum HTase/PON activity increased significantly in the three groups receiving intervention treatment (all P < 0.05)
PMID 17425871 · one of two readings recorded this
plasma total homocysteine, percentage decrease
decreases, p = 0.01
The Hcy level decreased by 2.8% in Group I, 14.0% in Group II, 37.3% in Group III, and 21.7% in Group IV respectively (all P < 0.01)
PMID 17425871 · one of two readings recorded this
serum HTase/PON activity, percentage increase
increases, p = 0.05
The HTase/PON activity increased by 2.7% in Group I, 8.0% in Group II, 3.4% in Group III, and 17.6% in Group IV respectively (all P < 0.05)
PMID 17425871 · one of two readings recorded this
fasting blood glucose (FBG)
modulates, p = 0.01
FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)
PMID 18257180 · one of two readings recorded this
FBG, GHB, hemorheological indexes, ET, NO and MDA, moxibustion versus acupuncture
no effect, p = 0.05
with no significant difference as compared with those in the acupuncture group (P > 0.05)
PMID 18257180 · one of two readings recorded this
FBG, GHB, hemorheological indexes, ET, NO and MDA, moxibustion versus medication
modulates, p = 0.05
but with a significant difference as compared with the medication group (P < 0.05)
PMID 18257180 · one of two readings recorded this
glycosylated hemoglobin (GHB)
modulates, p = 0.01
FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)
PMID 18257180 · one of two readings recorded this
hemorheological indexes
modulates, p = 0.01
FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)
PMID 18257180 · one of two readings recorded this
plasma endothelin (ET)
modulates, p = 0.01
FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)
PMID 18257180 · one of two readings recorded this
plasma malondialdehyde (MDA)
modulates, p = 0.01
FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)
PMID 18257180 · one of two readings recorded this
plasma nitric oxide (NO)
modulates, p = 0.01
FBG, GHB, hemorheological indexes, plasma ET, NO and MDA significantly improved in the mild-warm moxibustion group (P < 0.01)
PMID 18257180 · one of two readings recorded this
total effective rate
The total effective rate was 90.0%
PMID 18257180 · one of two readings recorded this
correlation between changes in HTase/PON activity and Hcy
decreases, p = 0.004
There was a significant inverse correlation between the changes in HTase/PON activity and Hcy levels (r=-0.29, P=0.004)
PMID 18781288 · one of two readings recorded this
plasma homocysteine after vitamin supplementation
decreases
After vitamin supplementation there was a significant reduction in plasma Hcy levels
PMID 18781288 · one of two readings recorded this
plasma homocysteine, diabetics versus controls
decreases, p = 0.05
Serum HTase/PON activity was significantly higher in diabetics compared with controls, plasma Hcy levels were significantly lower (P<0.05)
PMID 18781288 · one of two readings recorded this
plasma homocysteine, mean percentage reduction
decreases
The mean percentage reduction in Hcy was 2.75% in group I, 14% in group II and 37.3% in group III
PMID 18781288 · one of two readings recorded this
serum HTase/PON activity, diabetics versus controls
increases, p = 0.05
Serum HTase/PON activity was significantly higher in diabetics compared with controls, plasma Hcy levels were significantly lower (P<0.05)
PMID 18781288 · one of two readings recorded this
serum HTase/PON activity, percentage increase
increases, p = 0.001
A 2.72% increase in HTase/PON activity was seen in group I, an 8.03% increase was detected when folic acid was given in group II (P<0.001), and a 17.59% increase in HTase/PON activity was seen in group III (P<0.001)
PMID 18781288 · one of two readings recorded this
control rate
the control rate half a year after the treatment was 45.7%, 27.8%, 36.0%, respectively
PMID 19160857 · one of two readings recorded this
effective rate and control rate, intratympanic perfusion versus carbamazepine
no effect
There was no statistically significant difference in the effective rate and control rate between intratympanic perfusion group and carbamazepine group
PMID 19160857 · one of two readings recorded this
effective rate and control rate, prednisolone versus dexamethasone
modulates
There is a statistically significant difference both in the effective rate and the control rate between the prednisolone group and the dexamethasone group
PMID 19160857 · one of two readings recorded this
effective rate
The effective rate of the prednisolone group, dexamethasone group and the carbamazepine group was 48.6%, 33.3%, 44.0%, respectively
PMID 19160857 · one of two readings recorded this
urinary bother, UCLA-PCI
no effect, p = 0.168, n = 54
group A tended to have a better URF than group B (85.7 +/- 4.7 (mean +/- standard error) vs. 66.9 +/- 10.2) and URB (85.7 +/- 7.4 vs. 63.9 +/- 11.8) (p = 0.121, p = 0.168)
PMID 19198223 · one of two readings recorded this
urinary function, UCLA-PCI
no effect, p = 0.121, n = 54
group A tended to have a better URF than group B (85.7 +/- 4.7 (mean +/- standard error) vs. 66.9 +/- 10.2) and URB (85.7 +/- 7.4 vs. 63.9 +/- 11.8) (p = 0.121, p = 0.168)
PMID 19198223 · one of two readings recorded this
urinary function, urinary bother, sexual function and sexual bother on the UCLA Prostate Cancer Index after nerve sparing radical prostatectomy
no effect
Not recorded as a finding: this platform holds no node for the endpoint
There were no significant differences in URF, URB, SXF or SXB between the two groups at any postoperative period.
PMID 19198223 · both readings recorded this
urinary function, urinary bother, sexual function and sexual bother, UCLA-PCI
no effect
There were no significant differences in URF, URB, SXF or SXB between the two groups at any postoperative period
PMID 19198223 · one of two readings recorded this
LF
decreases
low frequency (LF, ms2) 379.90 +/- 159.07 vs 477.70 +/- 396.91
PMID 19213352 · one of two readings recorded this
clinical efficacy grade, clinically cured
while the corresponding data in the control group were 2 (8%), 4 (16%), 18 (72%) and 1 (4%) respectively
PMID 19213352 · one of two readings recorded this
clinical efficacy grade, clinically cured
5 patients (20%) were clinically cured
PMID 19213352 · one of two readings recorded this
clinical efficacy, treatment versus control
increases, p = 0.05, n = 50
demonstrating the efficacy in the treatment group was superior to that in the control group (P <0.05)
PMID 19213352 · one of two readings recorded this
HF
increases
high frequency (HF, ms2) 157.10 +/- 28.18 vs 122.10 +/- 101.90
PMID 19213352 · one of two readings recorded this
HRV indexes, all
modulates, p = 0.05
All were superior in the treatment group (P < 0.05)
PMID 19213352 · one of two readings recorded this
HRV indexes before treatment
no effect, p = 0.05
Before treatment, the HRV indexes in the two groups were insignificantly different respectively (P >0.05)
PMID 19213352 · one of two readings recorded this
HRVTI
increases
HRV trigonometric index (HRVTI) 35.10 +/- 4.48 vs 25.51 +/- 2.24
PMID 19213352 · one of two readings recorded this
LF/HF ratio
decreases
LF/HF ratio 2.37 +/- 0.52 vs 4.27 +/- 2.84
PMID 19213352 · one of two readings recorded this
SDANN
increases
average standard deviation of 5 min NN intervals (SDANN, ms) 126.90 +/- 9.99 vs 106.20 +/- 8.84
PMID 19213352 · one of two readings recorded this
SDNN
increases
standard deviation of NN intervals (SDNN, ms) 133.41 +/- 8.61 vs 115.61 +/- 13.49
PMID 19213352 · one of two readings recorded this
augmentation index in the carotid artery
decreases, p = 0.03
Not recorded as a finding: the sentence reports a change in only the methylcobalamin group, not a stated between-arm contrast (within_arm_only)
Augmentation index was decreased in only the methylcobalamin group (P = 0.03).
PMID 20430500 · both readings recorded this
augmentation index in the carotid artery
decreases, p = 0.03, n = 20
Augmentation index was decreased in only the methylcobalamin group (P = 0.03)
PMID 20430500 · one of two readings recorded this
normalization of plasma homocysteine (<15 umol/L)
increases, 18 of 20 vs 6 of 20 normalized, n = 40
Not recorded as a finding: no outcome node for plasma homocysteine
The proportion showing normalization of plasma homocysteine levels was much greater in the methylcobalamin group (18 of 20 patients; 90%) than in the folate group (6 of 20; 30%; P < 0.001).
PMID 20430500 · one of two readings recorded this
percentage decrease in serum ADMA
decreases, p = 0.001, n = 40
The percentage of decrease in ADMA levels was greater in the methylcobalamin than folate group (25.4% +/- 10.2% vs 13.2% +/- 11.2%; P < 0.001)
PMID 20430500 · one of two readings recorded this
plasma homocysteine normalization (<15 umol/L), proportion
increases, 18 of 20 (90%) vs 6 of 20 (30%)
Not recorded as a finding: No outcome node for homocysteine
The proportion showing normalization of plasma homocysteine levels was much greater in the methylcobalamin group (18 of 20 patients; 90%) than in the folate group (6 of 20; 30%; P < 0.001).
PMID 20430500 · one of two readings recorded this
proportion with normalization of plasma homocysteine (<15 mumol/L)
increases, p = 0.001, n = 40
The proportion showing normalization of plasma homocysteine levels was much greater in the methylcobalamin group (18 of 20 patients; 90%) than in the folate group (6 of 20; 30%; P < 0.001)
PMID 20430500 · one of two readings recorded this
ratio of dimethylamine to ADMA
increases, p = 0.04, n = 20
however, the ratio of dimethylamine to ADMA was increased in only the methylcobalamin group (P = 0.04)
PMID 20430500 · one of two readings recorded this
ratio of S-adenosylmethionine to S-adenosylhomocysteine
no effect, n = 40
The increase in ratio of S-adenosylmethionine to S-adenosylhomocysteine was not different between the 2 groups
PMID 20430500 · one of two readings recorded this
1-point (tactile) static testing of cutaneous sensitivity at the right and left great toe and heel
increases, n = 20
Statistically significant improvement in 1-point (tactile) and 2-point (discriminatory) static testing at the right and left great toe and heel in the patients was observed in all 3 follow-up periods
PMID 21206429 · one of two readings recorded this
2-point (discriminatory) static testing of cutaneous sensitivity at the right and left great toe and heel
increases, n = 20
Statistically significant improvement in 1-point (tactile) and 2-point (discriminatory) static testing at the right and left great toe and heel in the patients was observed in all 3 follow-up periods
PMID 21206429 · one of two readings recorded this
cutaneous sensitivity improvement, largest between follow-up periods
increases, n = 20
The greatest improvement occurred between baseline and 1 year of treatment
PMID 21206429 · one of two readings recorded this
fasting plasma total homocysteine
decreases
The supplement group had average plasma tHCY reduced to 9.3 ± 2.7 μmol/L
PMID 21216507 · one of two readings recorded this
Mattis dementia rating scale, global cognitive decline
no effect
Homocysteine lowering in dementia patients did not significantly reduce global cognitive decline
PMID 21216507 · one of two readings recorded this
MDRS construction domain decline
decreases, p = 0.003
the decline in MDRS (construction domain) was significantly smaller in the supplement group (median 0 versus 2 points in placebo group, P = 0.003)
PMID 21216507 · one of two readings recorded this
neuropsychological scores, change
no effect
There was no significant group difference in changes in any of the neuropsychological scores
PMID 21216507 · one of two readings recorded this
effective rate
increases, p = 0.05, n = 60
The effective rates were 90.0% (27/30) and 63.3% (19/30) in group A and group B respectively, presenting significant statistical difference (P < 0.05)
PMID 21823284 · one of two readings recorded this
motor and sensory nerve conduction velocity of ulnar and tibial nerve
increases, p = 0.05
the motor nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) of ulnar nerve and tibial nerve in group A were higher than those in group B (P < 0.05, P < 0.01)
PMID 21823284 · one of two readings recorded this
score of Chinese medicine syndrome
decreases, p = 0.01
the score of Chinese medicine syndrome in group A was lower than that in group B (14.36 +/- 1.88 vs 26.58 +/- 3.52, P < 0.01)
PMID 21823284 · one of two readings recorded this
score of diabetic peripheral neuropathy
decreases, p = 0.01
the score of diabetic peripheral neuropathy in group A was lower than that in group B (12.86 +/- 4.28 vs 17.89 +/- 4.35, P < 0.01)
PMID 21823284 · one of two readings recorded this
Oswestry Disability Index questionnaire Version 2.0, disability score
decreases
Not recorded as a finding: No outcome node for the Oswestry Disability Index
There was a significant improvement in the Oswestry Disability Index and Visual Analogue Scale pain scores in the methylcobalamin group as compared with the placebo group (p-value less than 0.05).
PMID 22159928 · one of two readings recorded this
Oswestry Disability Index questionnaire version 2.0 score
decreases
Not recorded as a finding: no outcome node for the Oswestry Disability Index
There was a significant improvement in the Oswestry Disability Index and Visual Analogue Scale pain scores in the methylcobalamin group as compared with the placebo group (p-value less than 0.05).
PMID 22159928 · one of two readings recorded this
Oswestry Disability Index
decreases, p = 0.05, n = 58
There was a significant improvement in the Oswestry Disability Index and Visual Analogue Scale pain scores in the methylcobalamin group as compared with the placebo group (p-value less than 0.05)
PMID 22159928 · one of two readings recorded this
Visual Analogue Scale pain score
decreases, p = 0.05, n = 58
There was a significant improvement in the Oswestry Disability Index and Visual Analogue Scale pain scores in the methylcobalamin group as compared with the placebo group (p-value less than 0.05)
PMID 22159928 · one of two readings recorded this
Total effective rate (recovery of lower limb sensation disorder)
increases, p = 0.05
The total effective rate was 90.0% (36/40) in plum-blossom needle group, superior to that of 60.0% (24/40) in western medication group (P < 0.05)
PMID 22493916 · one of two readings recorded this
Total effective rate (recovery of lower limb sensation disorder)
The total effective rate was 90.0% (36/40) in plum-blossom needle group, superior to that of 60.0% (24/40) in western medication group (P < 0.05)
PMID 22493916 · one of two readings recorded this
Total effective rate (recovery of lower limb sensation disorder)
no effect, p = 0.05
there was no significant differences between the cases which received the treatment during 1-3 months after operation and more than 3 months after operation (P > 0.05)
PMID 22493916 · one of two readings recorded this
Total effective rate (recovery of lower limb sensation disorder)
increases, p = 0.05
the effect for the cases which received treatment within one month after operation was superior to that received treatment during 1-3 months after operation (P < 0.05)
PMID 22493916 · one of two readings recorded this
total effectiveness rate and clinical cure rate, acupuncture versus other treatments including carbamazepine, mecobalamin and massage
increases
All studies reported that acupuncture was superior to other treatments, including carbamazepine, mecobalamin, and massage, and the meta-analysis on these low-quality studies yielded similar results
PMID 22875561 · one of two readings recorded this
Total effective rate (hearing improvement)
The total effective rate was 89.2% (66/74) in the warming-promoting needling group, which was better than 62.5% (35/56) in the conventional acupuncture group and 53.4% (31/58) in the medication group (both P<0.01)
PMID 23213981 · one of two readings recorded this
Total effective rate (hearing improvement)
The total effective rate was 89.2% (66/74) in the warming-promoting needling group, which was better than 62.5% (35/56) in the conventional acupuncture group and 53.4% (31/58) in the medication group (both P<0.01)
PMID 23213981 · one of two readings recorded this
Total effective rate (hearing improvement)
increases, p = 0.01
The total effective rate was 89.2% (66/74) in the warming-promoting needling group, which was better than 62.5% (35/56) in the conventional acupuncture group and 53.4% (31/58) in the medication group (both P<0.01)
PMID 23213981 · one of two readings recorded this
Neuropathy Total Symptom Score (NTSS-6) at weeks 16 and 24 in type 2 diabetes with neuropathy; vibration perception threshold was the primary endpoint
clinically significant improvement in NTSS-6 scores at week 16 (P=.013 vs placebo) and week 24 (P=.033), p = 0.033
Not recorded as a finding: the intervention held more than the compound
However, patients receiving LMF-MC-PLP consistently reported symptomatic relief, with clinically significant improvement in NTSS-6 scores at week 16 (P=.013 vs placebo) and week 24 (P=.033).
PMID 23218892 · one of two readings recorded this
Neuropathy Total Symptom Score (NTSS-6)
decreases, p = 0.013
clinically significant improvement in NTSS-6 scores at week 16 (P=.013 vs placebo) and week 24 (P=.033)
PMID 23218892 · one of two readings recorded this
Neuropathy Total Symptom Score (NTSS-6)
decreases, p = 0.033
clinically significant improvement in NTSS-6 scores at week 16 (P=.013 vs placebo) and week 24 (P=.033)
PMID 23218892 · one of two readings recorded this
Plasma homocysteine
decreases, p = 0.0001
Homocysteine decreased by 2.7±3.0 μmol/L with LMF-MC-PLP versus an increase of 0.5±2.4 μmol/L with placebo (P=.0001)
PMID 23218892 · one of two readings recorded this
Quality-of-life measures (SF-36)
increases
Quality-of-life measures also improved
PMID 23218892 · one of two readings recorded this
Vibration perception threshold (VPT)
no effect
There was no significant effect on VPT
PMID 23218892 · one of two readings recorded this
Mean numerical pain scale (NPS)
no effect
NPS scores were statistically similar by the end of 90 days
PMID 23279193 · one of two readings recorded this
Mean numerical pain scale (NPS)
decreases
Over the follow-up of 90 days, the mean NPS in group A decreased from 6 ± 2 to 3 ± 2 and in group B from 5 ± 1 to 2 ± 2
PMID 23279193 · one of two readings recorded this
Mean numerical pain scale (NPS)
decreases
Over the follow-up of 90 days, the mean NPS in group A decreased from 6 ± 2 to 3 ± 2 and in group B from 5 ± 1 to 2 ± 2
PMID 23279193 · one of two readings recorded this
Time to improvement in BPI emotion interference
decreases
Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)
PMID 23279193 · one of two readings recorded this
Time to improvement in BPI emotion interference
decreases
Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)
PMID 23279193 · one of two readings recorded this
Time to improvement in BPI interpersonal relationship interference
decreases
Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)
PMID 23279193 · one of two readings recorded this
Time to improvement in BPI interpersonal relationship interference
decreases
Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)
PMID 23279193 · one of two readings recorded this
Time to improvement in BPI mood interference
decreases
Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)
PMID 23279193 · one of two readings recorded this
Time to improvement in BPI mood interference
decreases
Improvement from baseline in BPI measurement of QOL (mood, interpersonal relationship, and emotion) was earlier in group B (1, 2, and 1 months, respectively) compared with group A (2, 3, and 2 months, respectively)
PMID 23279193 · one of two readings recorded this
Lequesne Index score
decreases, p = 0.05
Lequesne Index score, -0.60±0.06 versus -0.84±0.09, P=0.05
PMID 23354008 · one of two readings recorded this
Net change in AGEs
decreases, p = 0.001
AGEs, -0.12±0.02 versus -0.99±0.09, arbitrary florescence units, P=0.001
PMID 23354008 · one of two readings recorded this
Net change in C-reactive protein
decreases, p = 0.01
C-reactive protein, -0.12±0.35 versus -2.45±0.60 mg/L, P<0.01
PMID 23354008 · one of two readings recorded this
Net change in serum nitrite
decreases, p = 0.001
Net change in serum nitrite, -0.15±0.01 versus -0.79±0.12 µmol/L, P<0.001
PMID 23354008 · one of two readings recorded this
Net change in thiobarbituric acid reactive substances
decreases, p = 0.01
thiobarbituric acid reactive substances, -0.69±0.12 versus -1.80±0.12 nmol/L, P<0.01
PMID 23354008 · one of two readings recorded this
Net decrease in pain score
decreases, p = 0.003
At 24 weeks, net decrease in pain score, -6.64±2.71 versus -8.20±1.28, P=0.003
PMID 23354008 · one of two readings recorded this
Time taken for 20-m walk test
no effect, p = 1
time taken for 20-m walk test, -5.0±1.39 versus -5.0±0.92 s, P=1.00
PMID 23354008 · one of two readings recorded this
Total WOMAC score
decreases, p = 0.013
total WOMAC score, -5.88±0.84 versus -8.26±1.24, P=0.013
PMID 23354008 · one of two readings recorded this
activities of daily living and quality of life
increases, p = 0.001
Twenty subjects achieved pain reduction ≥ 50%, 24 perceived worst pain ≤ 3, 24 stopped using analgesics at end point; activities of daily living and quality of life improved significantly as compared with the other groups (P < 0.001)
PMID 23566267 · one of two readings recorded this
allodynia
decreases, p = 0.05
In the injected methylcobalamin group, the overall pain (P < 0.001), continuous spontaneous pain (P < 0.05), paroxysmal pain (P < 0.05), and allodynia (P < 0.05) revealed a significant effect at each follow-up point as compared with the other groups
PMID 23566267 · one of two readings recorded this
continuous spontaneous pain
decreases, p = 0.05
In the injected methylcobalamin group, the overall pain (P < 0.001), continuous spontaneous pain (P < 0.05), paroxysmal pain (P < 0.05), and allodynia (P < 0.05) revealed a significant effect at each follow-up point as compared with the other groups
PMID 23566267 · one of two readings recorded this
overall pain, time per group interaction and group difference
modulates, p = 0.001
Time per group interaction and group difference on overall pain at each follow-up point were statistically significant (P < 0.001) among groups
PMID 23566267 · one of two readings recorded this
overall pain
decreases, p = 0.001
In the injected methylcobalamin group, the overall pain (P < 0.001), continuous spontaneous pain (P < 0.05), paroxysmal pain (P < 0.05), and allodynia (P < 0.05) revealed a significant effect at each follow-up point as compared with the other groups
PMID 23566267 · one of two readings recorded this
pain relief
no effect, p = 0.05
Although both of the other groups showed a significant response after the 14-day treatment (P < 0.001) compared with the baseline, oral methylcobalamin did not provide any significantly pain relief (P > 0.05)
PMID 23566267 · one of two readings recorded this
pain response versus baseline after 14-day treatment
decreases, p = 0.001
Although both of the other groups showed a significant response after the 14-day treatment (P < 0.001) compared with the baseline, oral methylcobalamin did not provide any significantly pain relief (P > 0.05)
PMID 23566267 · one of two readings recorded this
paroxysmal pain
decreases, p = 0.05
In the injected methylcobalamin group, the overall pain (P < 0.001), continuous spontaneous pain (P < 0.05), paroxysmal pain (P < 0.05), and allodynia (P < 0.05) revealed a significant effect at each follow-up point as compared with the other groups
PMID 23566267 · one of two readings recorded this
subjects achieving pain reduction of 50% or more
increases
Twenty subjects achieved pain reduction ≥ 50%, 24 perceived worst pain ≤ 3, 24 stopped using analgesics at end point; activities of daily living and quality of life improved significantly as compared with the other groups (P < 0.001)
PMID 23566267 · one of two readings recorded this
subjects who stopped using analgesics
decreases
Twenty subjects achieved pain reduction ≥ 50%, 24 perceived worst pain ≤ 3, 24 stopped using analgesics at end point; activities of daily living and quality of life improved significantly as compared with the other groups (P < 0.001)
PMID 23566267 · one of two readings recorded this
subjects with worst pain 3 or less
decreases
Twenty subjects achieved pain reduction ≥ 50%, 24 perceived worst pain ≤ 3, 24 stopped using analgesics at end point; activities of daily living and quality of life improved significantly as compared with the other groups (P < 0.001)
PMID 23566267 · one of two readings recorded this
effectiveness
decreases
There was low and very low-quality evidence from six trials that multimodal nonoperative treatment is less effective than indirect or direct surgical decompression with or without fusion
PMID 23996271 · one of two readings recorded this
function
no effect
no significant difference in function at six months (mean difference (MD) -3.66, 95% CI -10.12 to 2.80)
PMID 23996271 · one of two readings recorded this
function
unclear
at 24 months a significant difference was found favouring decompression (MD -4.43, 95% CI -7.91 to -0.96)
PMID 23996271 · one of two readings recorded this
leg pain and function
increases
There was low-quality evidence from a single trial that exercise is of short-term benefit for leg pain and function compared with no treatment
PMID 23996271 · one of two readings recorded this
pain and other outcomes assessed
no effect
There was very low-quality evidence from six trials that calcitonin is no better than placebo or paracetamol, regardless of mode of administration or outcome assessed
PMID 23996271 · one of two readings recorded this
pain, function, and quality of life
increases
epidural steroid injections improved pain, function, and quality of life, up to two weeks, compared with home exercise or inpatient physical therapy
PMID 23996271 · one of two readings recorded this
walking distance
increases
very low-quality evidence for gabapentin or methylcobalamin that they improved walking distance
PMID 23996271 · one of two readings recorded this
walking distance
increases
very low-quality evidence for gabapentin or methylcobalamin that they improved walking distance
PMID 23996271 · one of two readings recorded this
walking distance
increases
From single small trials, there was low-quality evidence for prostaglandins, and very low-quality evidence for gabapentin or methylcobalamin that they improved walking distance
PMID 23996271 · one of two readings recorded this
DEB-NTC grade 1 neuropathy
In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases
PMID 24377531 · one of two readings recorded this
DEB-NTC grade 2 neuropathy
In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively
PMID 24377531 · one of two readings recorded this
DEB-NTC grade 2 neuropathy
In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases
PMID 24377531 · one of two readings recorded this
DEB-NTC grade 3 neuropathy
In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively
PMID 24377531 · one of two readings recorded this
DEB-NTC grade 3 neuropathy
In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases
PMID 24377531 · one of two readings recorded this
Incidence of neuropathy
p = 0.01
The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01)
PMID 24377531 · one of two readings recorded this
Incidence of neuropathy
decreases, p = 0.01
The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01)
PMID 24377531 · one of two readings recorded this
NCI-CTC grade 1 neuropathy
grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case
PMID 24377531 · one of two readings recorded this
NCI-CTC grade 1 neuropathy
Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases
PMID 24377531 · one of two readings recorded this
NCI-CTC grade 2 neuropathy
grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case
PMID 24377531 · one of two readings recorded this
NCI-CTC grade 2 neuropathy
Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases
PMID 24377531 · one of two readings recorded this
VAS
VAS was 4.9 ± 2.4
PMID 24377531 · one of two readings recorded this
VAS
VAS was 2.7 ± 2.2
PMID 24377531 · one of two readings recorded this
efficacy
increases
PGE1-MC combination therapy was significantly better than MC monotherapy (RR = 1.40; 95 % CI 1.33-1.48) on efficacy
PMID 24522613 · one of two readings recorded this
median motor nerve conduction velocity
increases
6.72 (95 % CI: 5.42-8.02) for median motor nerve conduction velocity (MNCV)
PMID 24522613 · one of two readings recorded this
median sensory nerve conduction velocity
increases
5.13 (CI 4.13-6.13) for median sensory nerve conduction velocity (SNCV)
PMID 24522613 · one of two readings recorded this
peroneal motor nerve conduction velocity
increases
5.74 (CI 4.87-6.61) for peroneal MNCV
PMID 24522613 · one of two readings recorded this
peroneal sensory nerve conduction velocity
increases
4.62 (CI 3.89-5.34) for peroneal SNCV
PMID 24522613 · one of two readings recorded this
efficiency by age
increases
Regard of age, the efficiency of NGF treatment group was significantly higher than control group
PMID 25129979 · one of two readings recorded this
efficiency, high pre-treatment PTA
no effect
For the patients whose duration were more than 7 d, or the PTA>60 dBHL, the efficiency of NGF therapy was not superior to the traditional treatment
PMID 25129979 · one of two readings recorded this
efficiency, long duration
no effect
For the patients whose duration were more than 7 d, or the PTA>60 dBHL, the efficiency of NGF therapy was not superior to the traditional treatment
PMID 25129979 · one of two readings recorded this
efficiency, low pre-treatment PTA
increases
For the patients whose duration were less than 7 d, or the PTA < or = 60 dBHL, the efficiency of NGF group were significantly higher
PMID 25129979 · one of two readings recorded this
efficiency, short duration
increases
For the patients whose duration were less than 7 d, or the PTA < or = 60 dBHL, the efficiency of NGF group were significantly higher
PMID 25129979 · one of two readings recorded this
total efficiency
increases, n = 115
The total efficiency of NGF group was significantly higher than control group
PMID 25129979 · one of two readings recorded this
JOA score
unclear, p = 0.05
The JOA score at 6 months of followed-ups was superior in the treatment group to that of the control group (P < 0.05)
PMID 25137843 · one of two readings recorded this
JOA score
unclear
The JOA scores were improved after treatment, at 6 and 12 months of followed-ups (P < 0.05, P < 0.01)
PMID 25137843 · one of two readings recorded this
occurrence of failed back surgery syndrome, group comparison
decreases, p = 0.05
The treatment group was superior to the control group (P < 0.05)
PMID 25137843 · one of two readings recorded this
occurrence of failed back surgery syndrome
decreases
Five patients (accounting for 10.6%) suffered from FBSS in the treatment group, while 9 (accounting for 19.6%) suffered from FBSS in the control group
PMID 25137843 · one of two readings recorded this
patients completing follow-up
n = 93
Totally 93 patients completed the followed-up study
PMID 25137843 · one of two readings recorded this
serum TNF-alpha level, group comparison
unclear, p = 0.05
the improvement of TNF-alpha in the treatment group was better than that of the control group (P < 0.05)
PMID 25137843 · one of two readings recorded this
serum TNF-alpha level
unclear
The TNFalpha level was improved after treatment in the two groups
PMID 25137843 · one of two readings recorded this
Medical Research Council (MRC) sum score in at least two of 20 muscles, open-label single-arm, 1 year after intravenous methylcobalamin
improved in seven of twelve evaluated patients, unchanged or worsened in five
Not recorded as a finding: this platform holds no node for the endpoint
Therefore, twelve patients were evaluated for the primary outcomes; the MRC sum score was improved in seven of the patients and unchanged or worsened in the remaining five patients.
PMID 25175124 · one of two readings recorded this
MRC sum score improvement in at least two of 20 muscles
increases
Therefore, twelve patients were evaluated for the primary outcomes; the MRC sum score was improved in seven of the patients and unchanged or worsened in the remaining five patients
PMID 25175124 · one of two readings recorded this
clinical symptoms and signs, cold water loading test and electroneuromyography
increases, p = 0.05
significant improvements in clinical symptoms and signs (hand numbness and pain, and reduced senses of touch, pain, and vibration), cold water loading test (CWLT), and electroneuromyography (ENMG) after treatments (P < 0.05)
PMID 25608899 · one of two readings recorded this
clinical symptoms and signs, cold water loading test and electroneuromyography
increases, p = 0.05
significant improvements in clinical symptoms and signs (hand numbness and pain, and reduced senses of touch, pain, and vibration), cold water loading test (CWLT), and electroneuromyography (ENMG) after treatments (P < 0.05)
PMID 25608899 · one of two readings recorded this
improvement, treatment group versus control group
increases, p = 0.05
And the treatment group had significantly more improvements than the control group (P < 0.05)
PMID 25608899 · one of two readings recorded this
Median motor nerve conduction velocity (MNCV)
increases, p = 0.0001
The pooled WMD was 7.53, 95% CI was 4.65–10.42, Z was 5.11 (P < 0.0001)
PMID 25866802 · one of two readings recorded this
Median sensory nerve conduction velocity (SNCV)
increases, p = 0.003
The pooled WMD was 4.98, 95% CI was 1.75–8.21, Z was 3.02 (P = 0.003)
PMID 25866802 · one of two readings recorded this
Overall effectiveness (total efficiency)
increases, p = 0.0001
fixed effects model was employed for pooled analysis which showed that OR was 5.01, 95% CI was 3.70–6.78, Z was 10.44 (P < 0.0001)
PMID 25866802 · one of two readings recorded this
Peroneal motor nerve conduction velocity (MNCV)
increases, p = 0.0001
The pooled OR was 6.20, 95% CI was 4.69–7.72, Z was 8.02 (P < 0.0001)
PMID 25866802 · one of two readings recorded this
Peroneal sensory nerve conduction velocity (SNCV)
increases, p = 0.0001
The pooled OR was 4.06, 95% CI was 2.80–5.32, Z was 6.33 (P < 0.0001)
PMID 25866802 · one of two readings recorded this
average pain duration before presenting to hospital
Average pain duration before presenting to hospital is 260 min
PMID 25923150 · one of two readings recorded this
complete pain relief
no effect, p = 0.25
84% of group A and 76% of group B had complete pain relief at the end of 3 hours (P = .25)
PMID 25923150 · one of two readings recorded this
complete pain relief
no effect, p = 0.75
Sixteen percent in group A and 18% in group B had complete pain relief within 30 min (P = .75)
PMID 25923150 · one of two readings recorded this
decrease in pain by each scoring method (VAS, verbal and facial response scales)
no effect, p = 0.75
Decrease in pain by each scoring method was also comparable (P = .75)
PMID 25923150 · one of two readings recorded this
patients needing rescue drugs
Fifteen patients in group A and 13 patients in group B needed rescue drugs
PMID 25923150 · one of two readings recorded this
proportion of men in the study population
81% of the study population were men
PMID 25923150 · one of two readings recorded this
incidence of postherpetic neuralgia (PHN)
The incidence of postherpetic neuralgia (PHN) was 2.04% at 3 months
PMID 26200815 · one of two readings recorded this
mean pain score
The mean pain scores in A1 (2.6 ± 0.7) and B1 (1.2 ± 0.8) decreased significantly compared with those in A0 (7.0 ± 1.7) and B0 (5.6 ± 1.9)
PMID 26200815 · one of two readings recorded this
mean pain score
decreases
The mean pain scores in A1 (2.6 ± 0.7) and B1 (1.2 ± 0.8) decreased significantly compared with those in A0 (7.0 ± 1.7) and B0 (5.6 ± 1.9)
PMID 26200815 · one of two readings recorded this
mean pain score
The mean pain scores in A1 (2.6 ± 0.7) and B1 (1.2 ± 0.8) decreased significantly compared with those in A0 (7.0 ± 1.7) and B0 (5.6 ± 1.9)
PMID 26200815 · one of two readings recorded this